For research use only. Not for therapeutic Use.
Alpelisib（Cat No.:I000827）is a selective PI3K-alpha inhibitor used in the treatment of advanced or metastatic breast cancer. It targets the phosphoinositide 3-kinase (PI3K) pathway, which is often mutated in cancer cells, leading to uncontrolled growth and survival. By inhibiting this pathway, Alpelisib reduces tumor cell proliferation and induces apoptosis. It is particularly effective in patients with PIK3CA-mutated breast cancer, offering a targeted therapy option. Alpelisib, combined with endocrine therapy, has shown significant efficacy in delaying disease progression, making it a crucial drug in oncology.
| Catalog Number | I000827 |
| CAS Number | 1217486-61-7 |
| Synonyms | (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide |
| Molecular Formula | C19H22F3N5O2S |
| Purity | 98% |
| Target | PI3K |
| Target Protein | P42336 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | p110α：5 nM (IC50) |
| IUPAC Name | (2S)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide |
| InChI | InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1 |
| InChIKey | STUWGJZDJHPWGZ-LBPRGKRZSA-N |
| SMILES | CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F |
